ASCO 2018 Report — Breast Cancer

Highlights of the latest treatments

At this year's meeting of the American Society of Clinical Oncology (ASCO 2018), held June 1 to 5 in Chicago, investigators discussed the latest findings in cancer research. The editors of NEJM Journal Watch Oncology and Hematology were on hand to report highlights of the conference. Here, Editor-in-Chief William J. Gradishar, MD, reviews key presentations on new breast cancer therapies. All meeting abstracts can be viewed in the ASCO meeting library.

Sacituzumab Govitecan for Refractory HR+/HER2− Metastatic Breast Cancer

Bardia and colleagues conducted a phase I/II trial to evaluate the efficacy of the Trop-2 antibody-drug conjugate sacituzumab govitecan in patients with treatment-refractory, HR+/HER2− metastatic breast cancer (abstract 1004…

Author

William J. Gradishar, MD

Disclosures

Consultant/Advisory BoardLilly; AstraZeneca; Gilead

Grant/Research SupportBreast Cancer Research Foundation

Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment

Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)